Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).

Key Points

  • 25 patients with advanced...

Read more: Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

More Articles …

  1. Thunderhead expands APAC footprint with hire of industry thought leader Aarron Spinley, VP ANZ
  2. Welsh Developments ACTC Pty Ltd Announces Offering of AUD 142,726,327 Senior Secured Loan Note Offer
  3. Adyen to partner with Hungry Jack's to improve its customer service with payment-led updates
  4. Trineo Joins B Corp™ Community; Pledges To Use Business As Force For Good
  5. Over 65 speakers across 8 countries address critical themes of 'Readiness', 'Security' and 'Transparency' at URAP2 conference
  6. Novotech Health Holdings Announces Appointment of Anand Tharmaratnam as Chairman
  7. eSalon, The First and Only Custom Home Hair Colour Company, Expands Its One-of-a-Kind, Salon-Quality Products and Service to Australia New Zealand
  8. One third of Australians approaching retirement have never received any advice reveals Smart
  9. TTC Announces Two New Senior Appointments to Bolster New Zealand Presence
  10. Indosat Ooredoo partners with Comviva, the leader in mobility solutions to accelerate growth